Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.

Amanthi Nadira Arumahandi de Silva Leonie Maria Frommert Fredrik Nils Albach Jens Klotsche Veronika Scholz Lara Maria Jeworowski Tatjana Schwarz Alexander Ten Hagen Jan Zernicke Victor Max Corman Christian Drosten Gerd-Rüdiger R Burmester Robert Biesen

Published in: Annals of the rheumatic diseases (2022)

MTX reduces the immunogenicity of SARS-CoV-2 vaccination in an age-dependent manner. Our data further suggest that holding MTX for at least 10 days after vaccination significantly improves the antibody response in patients over 60 years of age.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
chronic kidney disease
newly diagnosed
respiratory syndrome coronavirus
peritoneal dialysis
prognostic factors
high dose
electronic health record
low dose
machine learning
middle aged